Purpose {#sec1}
=======

Orbital rhabdomyosarcoma (RMS) is the most common primary orbital malignancy in children and typically occurs in the first decade of life \[[@cit0001]\]. Till the late 70's, orbital RMS was typically managed with exenteration and was associated with poor prognosis and functional outcome. Currently, it is best managed with a combination of multi-agent chemotherapy (CTh) and external beam radiotherapy (EBRT) resulting in a 5-year survival exceeding 90% \[[@cit0002], [@cit0003]\]. However, EBRT is feared (necessarily or not) by most for its late toxicities of cranio-facial deformities, visual/orbital adverse effects and neuroendocrine sequelae especially in very young children \[[@cit0004], [@cit0005], [@cit0006]\]. Attempts to delay or omit EBRT have been sought with higher rates of local recurrence \[[@cit0007]\]. Brachytherapy with its steep dose fall off, provides an advantage over EBRT in reducing doses to orbit and neurological structures, and thereby potentially reducing the late sequelae of EBRT. However, it can be technically challenging and most reports of orbital brachytherapy are in the peri-operative setting, performed after surgical debulking \[[@cit0004], [@cit0008], [@cit0009], [@cit0010], [@cit0011], [@cit0012], [@cit0013]\]. Such procedures are challenging and carry the potential morbidities of both treatment modalities, i.e. surgery and brachytherapy.

We report the technical details of an innovative technique developed at our institute for interstitial brachytherapy of the orbit.

Material and methods {#sec2}
====================

Case details {#sec2.1}
------------

A 4 month old male patient presented to the Tata Memorial Hospital with complaints of redness and swelling at medial canthus of the left eye, which extended along the upper and lower eyelids ([Figure 1A](#f0001){ref-type="fig"}). Magnetic resonance imaging (MRI) of the orbit showed a homogenous lesion of 2.2 × 2.0 × 2.2 cm in the extraconal compartment of medial aspect of left orbit. The lesion was limited to the orbit without any intracranial extension, or extension into the ethmoid air sinuses ([Figures 1B](#f0001){ref-type="fig"} and [1C](#f0001){ref-type="fig"}). Biopsy was suggestive of alveolar rhabdomyosarcoma, which was positive for PAX3-FKHR fusion gene. Metastatic workup done with whole body positron emission tomography-computed tomography (PET-CT) was negative. The patient was treated with multi-agent chemotherapy as per the IRS-IV protocol \[[@cit0003]\]. The alveolar histology and suboptimal response after induction CTh mandated the use of radiation therapy for local control. In view of the expected morbidity of EBRT, it was decided to treat this patient using interstitial brachytherapy.

![**A)** Clinical presentation showing redness and swelling at medial canthus of left eye. **B and C)** Magnetic resonance imaging of the orbit (T2W axial and coronal) showing homogenous extraconal lesion involving the medial aspect of left orbit](JCB-9-30864-g001){#f0001}

Pre-planning {#sec2.2}
------------

Before embarking on the actual implantation procedure, a pre-planning was done to determine ideal catheter positions, safe depth for each catheter, and first/guide catheter position.

With the patient under sedation and the neck in neutral position, the patient was immobilized using a thermoplastic mould and CT images with slice thickness of 1 mm were obtained on a dedicated CT simulator. Clinical target volume (CTV) was delineated based on the disease extent visible on the planning CT images and modified using the pre CTh MRI. Brachytherapy treatment plans were generated using straight and uniformly spaced catheters placed along the target volume, to get the desired dose distribution. Nasion served as a reference for the first/guide catheter ([Figures 2A-C](#f0002){ref-type="fig"}). This guide catheter would then serve as a reference for subsequent catheter positions. Safe penetration depth for each catheter was determined on the axial CT cuts ([Figures 2D-F](#f0002){ref-type="fig"}).

![**A)** Preplanning images. First/guide catheter entry point determined by measuring the distance from midpoint of the nasion. **B and C)** All catheter positions determined with reference to the guide catheter. **D-F)** Measurement of penetration depth for different catheters](JCB-9-30864-g002){#f0002}

Implantation technique {#sec2.3}
----------------------

With the patient under general anesthesia (G.A.), needle entry points were extrapolated and marked on the skin as determined from the pre-planning CT scan ([Figure 3A](#f0003){ref-type="fig"}). The midline, nasion, and bony orbit were used as reference. A customized thermoplastic retainer for the brachytherapy catheters was fashioned in the operating room with the patient in the treatment position ([Figure 3B](#f0003){ref-type="fig"}). This retainer would be required to maintain the implant in place throughout the period of delivery, i.e. 4-5 days. The catheter entry points were then transferred onto the retainer ([Figure 3C](#f0003){ref-type="fig"}). This retainer would be fastened to the head of the patient using Velcro straps after the procedure.

![**A)** Entry points marked on patient. **B)** Fabrication of thermoplastic retainer. **C)** Extrapolation of catheter points onto the retainer](JCB-9-30864-g003){#f0003}

Using washers to guide the depth of implantation ([Figure 4A](#f0004){ref-type="fig"}), determined on the pre-planning CT scan, five brachytherapy catheters (189.601 ProGuide Needle Set 6F, sharp, (Oncentra Brachy, Elekta AB, Stockholm, Sweden) \[[@cit0014]\]) were implanted carefully, without injuring the eyeball ([Figures 4A-C](#f0004){ref-type="fig"}). Each catheter was then carefully passed through the holes drilled into the retainer, which was then guided over the catheters and positioned to fit snugly on the patients face. The catheters were secured using washers and glue. The retainer was secured in place using Velcro straps ([Figure 4D](#f0004){ref-type="fig"}).

![Implantation technique. **A-C)** Catheters with washers to guide the depth of insertion. **D)** Positioning of retainer over the catheters](JCB-9-30864-g004){#f0004}

Results {#sec3}
=======

Planning and dose prescription {#sec3.1}
------------------------------

After the procedure in the operating room, the patient was transferred to MRI suite under G.A. and a planning MRI was done using 3D FSPGR (three-dimensional fast spoiled gradient recall) sequences of 1 mm slice thickness and 0 mm gap. Clinical target volume was delineated on the planning images as previously described. ^192^Ir high-dose-rate (HDR) brachytherapy plan was generated using Oncentra brachytherapy planning system (Oncentra Brachy, Elekta AB, Stockholm, Sweden). The dose distribution was evaluated and optimized using graphical optimization to ensure adequate coverage of the target volume by the reference isodose ([Figures 5A](#f0005){ref-type="fig"} and [5B](#f0005){ref-type="fig"}). The plan was evaluated using dose volume histogram (DVH) for target volume coverage and dose to the critical structures ([Table 1](#t0001){ref-type="table"}). A total dose of 32 Gy was delivered using 4 Gy fractions (two fractions per day) over 4.5 days. For dosimetric comparison with EBRT, a RapidArc (Eclipse, Varian Medical Systems, Palo Alto, CA) plan was generated using a 3 mm PTV margin to the CTV ([Figures 5C](#f0005){ref-type="fig"} and [5D](#f0005){ref-type="fig"}). The dosimetric comparison between brachytherapy and EBRT are highlighted in [Table 1](#t0001){ref-type="table"}, and shows dosimetric superiority of brachytherapy for target volume and OAR's.

###### 

Dosimetric parameters of external beam radiotherapy and brachytherapy plans

  Structures                    EBRT rapid arc(%)   Brachytherapy(%)
  ----------------------------- ------------------- ------------------
  CTV (mean dose)               101                 158
  CTV D~90~                     100                 92
  CTV V~100~                    95                  90
  CTV V~150~                    --                  30
  CTV V~200~                    --                  16
  DHI                           --                  66
  Eye left (mean dose)          61                  61
  Lens left (mean dose)         66                  51
  Optic nerve left (max dose)   72                  54
  Bony orbit left (mean dose)   68                  39
  Pituitary gland (mean dose)   42                  6

EBRT -- external beam radiotherapy, BT -- brachytherapy, CTV -- clinical target volume, D~90~ -- minimum dose received by 90% of the target volume, V~100~ -- volume receiving by 100% of the prescription dose, V~150~ -- volume receiving by 150% of the prescription dose, V~200~ -- volume receiving by 200% of the prescription dose, DHI (dose homogeneity index) -- (V~100~--V~150~)/V~100~

![**A and B)** High-dose-rate brachytherapy plan on magnetic resonance imaging sequences (isodose lines: yellow -- 100% and green -- 50%). **C and D)** Rapid arc external beam radiotherapy (EBRT) plan (isodose wash: orange -- 95%, dark blue -- 50%). Note higher doses to pituitary and bony orbit with EBRT](JCB-9-30864-g005){#f0005}

Treatment delivery and follow-up {#sec3.2}
--------------------------------

The patient was treated twice daily using sedation, with a minimum 6 hours gap between fractions. Care was taken to ensure avoidance of handling of the retainer by the child. Oral analgesics and antibiotics were continued till the end of treatment. Acute reactions were minimal and consisted of mild skin erythema ([Figure 6A](#f0006){ref-type="fig"}).

![**A and B)** Acute and late skin changes, respectively. Note the preservation of eyebrows and excellent cosmetic outcome. **C and D)** Post-treatment T2W axial and coronal MRI showing complete regression of tumor](JCB-9-30864-g006){#f0006}

First follow-up was done at 3 months post brachytherapy. MRI scan of the orbit done at follow-up, showed a complete response with no evidence of disease ([Figure 6C](#f0006){ref-type="fig"} and [6D](#f0006){ref-type="fig"}). The patient has completed all treatment and is currently on regular follow-up, and has excellent cosmetic and functional outcome without any restriction of ocular mobility, dryness of the eye, or watering ([Figure 6B](#f0006){ref-type="fig"}). Flow-chart of the procedure is represented in [Figure 7](#f0007){ref-type="fig"}.

![Flowchart of the procedure](JCB-9-30864-g007){#f0007}

Discussion {#sec4}
==========

Multiagent chemotherapy and EBRT is the current management standard for orbital RMS. External beam radiotherapy has limitations like prolonged treatment of 5-6 weeks, anesthesia for young children, higher doses to unaffected surrounding ocular, bony and intracranial structures, and late toxicities like orbital hypoplasia, facial asymmetry, cataract, dry eye, eye lash loss, and endocrine abnormalities \[[@cit0004], [@cit0005], [@cit0006]\]. Even with the best of EBRT techniques like intensity-modulated radiotherapy (IMRT) or proton beam therapy (PBT), a significant dose is received by surrounding orbital structures \[[@cit0015]\].

Brachytherapy with its rapid dose fall-off beyond the catheters allows the delivery of optimal dose to the target while minimizing the dose to surrounding orbital structures and thus, reducing consequential late toxicities \[[@cit0008], [@cit0009]\]. Brachytherapy seems to offer an edge even over PBT in reducing doses to the bony orbit. Indirect comparison with dosimetric data of PBT from Yock *et al.* \[[@cit0015]\] shows significantly lower average doses to bony orbit with brachytherapy. This may result in a potentially reduced risk of skeletal deformities and second malignancies. Higher intratumoral doses with brachytherapy results in higher average doses to the target volume and may potentially enhance local control. There are also other advantages, like reduced overall treatment time, reduced requirement of anesthesia, and reduced requirement of strict immobilization.

The implantation technique reported in this article provides a detailed approach to an innovative way of interstitial brachytherapy of extraconal orbital tumors, and unlike other previous reports of orbital brachytherapy, does not require surgical debulking and surgical access for implantation \[[@cit0008], [@cit0009], [@cit0010], [@cit0011], [@cit0012], [@cit0013], [@cit0016]\]. Blank *et al.* \[[@cit0008]\] in a group of 20 children with RMS, have described the use of mold brachytherapy intraoperatively following macroscopic resection with minimal late toxicity. Various innovative techniques of interstitial brachytherapy for orbital tumors have also been reported previously \[[@cit0010], [@cit0011], [@cit0013], [@cit0016]\], with excellent local control and functional outcomes. These reported techniques have been either in combination of function preserving surgery \[[@cit0011], [@cit0013], [@cit0016]\] or after enucleation for melanomas with extra scleral disease extension \[[@cit0010]\].

With careful case selection and optimum pre-planning, this technique appears to be safe and effective option for radiation therapy even in infants. The relative contraindications of this method would include tumors in close proximity to the optic nerve and tumors adjacent to the orbital apex. Though a long term follow-up would be optimal to assess the effects on visual acuity, ocular motility and orbital development, the early outcomes in terms of disease control, cosmesis, and functional outcome have been encouraging.

Conclusions {#sec5}
===========

Orbital brachytherapy with its potential benefits of reduced late toxicities and shorter duration of treatment, is an attractive treatment option for very young children with orbital tumors, and should be considered as an alternative to EBRT whenever feasible. Extraconal tumors are best suited for interstitial brachytherapy technique reported in this manuscript. Implementation of this technique as a standard protocol for localized extraconal orbital tumors is being implemented at our institute. We have further improved our retainer stability and comfort, and also propose to make the procedure safer and more accurately reproducible using ultrasonography guidance for catheter insertion in the future.
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